Home Neoplasma 2015 Neoplasma Vol.62, No.3, p.353-364, 2015

Journal info


6 times a year.
Founded: 1954
ISSN 0028-2685
ISSN 1338-4317 (online)

Published in English

Editorial Info
Abstracted and Indexed
Submission Guidelines

Select Journal







Webshop Cart

Your Cart is currently empty.

Info: Your browser does not accept cookies. To put products into your cart and purchase them you need to enable cookies.

Neoplasma Vol.62, No.3, p.353-364, 2015

Title: RAGE and its ligands in cancer – culprits, biomarkers, or therapeutic targets?
Author: P. TESAROVA, M. CABINAKOVA, V. MIKULOVA, T. ZIMA, M. KALOUSOVA

Abstract: Receptor for advanced glycation end products (RAGE) plays a central role in the regulation of tissue homeostasis, regeneration and resolution of inflammation, but under pathological conditions RAGE-mediated pathways may induce diminished apoptosis, but enhanced autophagy and cell necrosis. These mechanisms may contribute to malignant transformation, cancer progression and metastases. Soluble RAGE may bind natural RAGE ligands and counteract some of the RAGE-mediated effects. Activation of RAGE was demonstrated in different types of cancer (including colon, pancreatic and breast cancer). Expression of RAGE and serum levels of soluble RAGE may serve as cancer biomarkers and strategies aimed at interfering with RAGE signaling might be promising anticancer drugs.

Keywords: RAGE, cancer, HMGB1, S100 proteins
Published online: 11-May-2015
Year: 2015, Volume: 62, Issue: 3 Page From: 353, Page To: 364
doi:10.4149/neo_2015_061


download file



© AEPress s.r.o
Copyright notice: For any permission to reproduce, archive or otherwise use the documents in the ELiS, please contact AEP.